Tilray, Inc. Series 2 Stock News

As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal government.

President Donald Trump's move to relax federal marijuana regulations has been welcomed by the US cannabis industry, but it has not changed the sector's most persistent challenge. Access to mainstream banking remains limited, even as regulatory pressure eases, reports Reuters.

U.S. President Donald Trump's move to relax marijuana regulations could ease some burden for cannabis companies, but will likely keep doors to access capital from big banks closed, experts said.

Expand NASDAQ: TLRY Tilray Brands Today's Change (-4.04%) $-0.52 Current Price $12.36 Key Data Points Market Cap $1.5B Day's Range $12.10 - $15.68 52wk Range $3.51 - $23.20 Volume 1.5M Avg Vol 10M Gross Margin 20.17% Tilray Brands (TLRY 4.04%), a global medical cannabis producer, closed Thursday at $12.34, down 4.2%. Tilray Brands IPO'd in 2018 and has fallen 94% since going public.

President Donald Trump on Thursday signed an executive order directing the federal government to move marijuana from Schedule I to Schedule III, potentially easing regulatory and financial constraints for cannabis companies while keeping recreational use illegal under federal law. The order instructs the attorney general to expedite the ongoing process of rescheduling marijuana, which is curren...

It has officially happened, Donald J Trump has signed the executive order to reschedule cannabis. Now, cannabis has been taken from a Class 1 to a Class 3 substance under the Controlled Substances. At this time, there is more to come in terms of what will take place specifically for legal operators and the cannabis industry overall. This push for reform has been ongoing for over a decade, and n...

President Donald Trump signed an executive order on Thursday directing federal agencies to reclassify marijuana from Schedule I to Schedule III. The move sent US cannabis stocks sharply higher on expectations of lighter regulation and expanded medical research.

Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare